Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst Upgrade

Kura Oncology, Inc. (NASDAQ:KURA) saw unusually-strong trading volume on Friday after HC Wainwright raised their price target on the stock from $32.00 to $37.00. HC Wainwright currently has a buy rating on the stock. Approximately 1,545,867 shares changed hands during trading, an increase of 59% from the previous session’s volume of 970,186 shares.The stock last traded at $10.83 and had previously closed at $10.06.

KURA has been the topic of several other reports. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday, November 19th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.38.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in KURA. nVerses Capital LLC bought a new stake in Kura Oncology during the third quarter valued at approximately $25,000. Aaron Wealth Advisors LLC grew its position in shares of Kura Oncology by 2.4% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after acquiring an additional 1,673 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares in the last quarter. Hsbc Holdings PLC raised its holdings in Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Kura Oncology by 17.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after purchasing an additional 2,940 shares in the last quarter.

Kura Oncology Stock Up 7.4 %

The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $17.88 and a 200-day simple moving average of $19.69. The firm has a market cap of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.